DWORF Positive Control for STJ500801 peptide (STJ505400)

SKU:
STJ505400-5

Shipping:
Free Shipping
Current Stock:
Applications: WB
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: DWORF Positive Control for STJ500801 is synthetically produced from the sequence and is suitable for use in western blot applications.
Formulation: Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is
Dilution Range: WB: 1:500
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: Strit1
Uniprot ID: DWORF_MOUSE
Specificity: This is positive control is recommended for use in combination with DWORF antibody STJ500801.
Tissue Specificity Highly expressed in heart (at protein level). Detected in heart and soleus, a postural muscle group of the hindlimb containing the highest enrichment of slow-twitch muscle fibers. Also expressed in diaphragm, which contains some slow-twitch fibers. Not detected in the quadriceps, a fast-twitch muscle group, or in cardiac atrial muscle. Not expressed in the prenatal heart but gradually increases in abundance postnatally.
Function Enhances the activity of ATP2A1/SERCA1 ATPase in sarcoplasmic reticulum by displacing ATP2A1/SERCA1 inhibitors, thereby acting as a key regulator of skeletal muscle activity. Also enhances the activity of the ATP2A2/SERCA2 ATPase. Does not directly stimulate SERCA pump activity. Binds preferentially to the phosphorylated E1 and E2 conformational forms of ATP2A2 which predominate at high Ca(2+) concentrations during the systolic phase of the cardiac cycle. Competes with ATP2A2 inhibitor phospholamban (PLN) for binding to ATP2A2 and displaces PLN. Can activate ATP2A2 directly in the absence of PLN. Also enhances sarcoplasmic reticulum Ca(2+) uptake and myocyte contractility by displacing the SERCA inhibitory peptides sarcolipin (SLN) and myoregulin (MRLN).
Peptide Name Sarcoplasmic/Endoplasmic Reticulum Calcium Atpase Regulator Dworf
Serca Regulator Dworf
Dwarf Open Reading Frame
Dworf
Small Transmembrane Regulator Of Ion Transport 1
Cellular Localisation Sarcoplasmic Reticulum Membrane
Single-Pass Membrane Protein
Alternative Peptide Names Sarcoplasmic/Endoplasmic Reticulum Calcium Atpase Regulator Dworf protein
Serca Regulator Dworf protein
Dwarf Open Reading Frame protein
Dworf protein
Small Transmembrane Regulator Of Ion Transport 1 protein
Strit1 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance